NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-450-1790
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8
Next Earnings Date12/11/2019 (Estimated)
OptionableNot Optionable
NeuBase Therapeutics (NASDAQ:NBSE) Frequently Asked Questions
What is NeuBase Therapeutics' stock symbol?
NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."
When is NeuBase Therapeutics' next earnings date?
What price target have analysts set for NBSE?
3 brokerages have issued 12 month price objectives for NeuBase Therapeutics' stock. Their forecasts range from $14.00 to $15.00. On average, they expect NeuBase Therapeutics' stock price to reach $14.33 in the next year. This suggests a possible upside of 103.9% from the stock's current price. View Analyst Price Targets for NeuBase Therapeutics.
What is the consensus analysts' recommendation for NeuBase Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeuBase Therapeutics.
Has NeuBase Therapeutics been receiving favorable news coverage?
Media coverage about NBSE stock has been trending somewhat positive on Thursday, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeuBase Therapeutics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for NeuBase Therapeutics.
Are investors shorting NeuBase Therapeutics?
NeuBase Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 108,000 shares, an increase of 23.7% from the October 31st total of 87,300 shares. Based on an average trading volume of 68,200 shares, the short-interest ratio is presently 1.6 days. Approximately 1.0% of the company's shares are short sold. View NeuBase Therapeutics' Current Options Chain.
Who are some of NeuBase Therapeutics' key competitors?
Some companies that are related to NeuBase Therapeutics include Sinovac Biotech (SVA), Organogenesis (ORGO), Aptorum Group (APM), Dermira (DERM), Morphic (MORF), Emisphere Technologies (EMIS), Progenics Pharmaceuticals (PGNX), Ardelyx (ARDX), Evolus (EOLS), Assembly Biosciences (ASMB), Milestone Pharmaceuticals (MIST), DURECT (DRRX), Merus (MRUS), BioSpecifics Technologies (BSTC) and Stealth BioTherapeutics (MITO).
Who are NeuBase Therapeutics' key executives?
NeuBase Therapeutics' management team includes the folowing people:
- Dr. Dietrich A. Stephan Ph.D., Founder, Chairman & CEO
- Mr. Samuel Backenroth, CFO & Sr. VP of Bus. Devel. (Age 35)
- Dr. Danith H. Ly, Chief Scientific Officer
- Robert Friedlander, Consulting Chief Medical Officer
- Robert Zamboni, Chief of Preclinical Devel.
Who are NeuBase Therapeutics' major shareholders?
NeuBase Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.07%) and Heritage Wealth Advisors (0.06%).
Which institutional investors are buying NeuBase Therapeutics stock?
NBSE stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Heritage Wealth Advisors.
How do I buy shares of NeuBase Therapeutics?
Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NeuBase Therapeutics' stock price today?
One share of NBSE stock can currently be purchased for approximately $7.03.
How big of a company is NeuBase Therapeutics?
What is NeuBase Therapeutics' official website?
How can I contact NeuBase Therapeutics?
NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company can be reached via phone at 646-450-1790 or via email at [email protected]
MarketBeat Community Rating for NeuBase Therapeutics (NASDAQ NBSE)
MarketBeat's community ratings are surveys of what our community members think about NeuBase Therapeutics and other stocks. Vote "Outperform" if you believe NBSE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBSE will underperform the S&P 500 over the long term. You may vote once every thirty days.
